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Abstract 18 
 19 
Recent genomic studies have revealed the highly polygenic nature of psychiatric disorders 20 
including schizophrenia, bipolar disorder, and major depressive disorder. Many of the 21 
individual genetic associations are shared across multiple disorders in a way that points to 22 
extensive biological pleiotropy, and further challenges the biological validity of existing 23 
diagnostic approaches. Here, we argue it is unlikely that risk alleles exist that are specific to 24 
a single diagnostic category. We also highlight some of the important clinical repercussions 25 
of pleiotropy.  26 
 27 
 28 
 29 
Introduction  30 
 31 
Psychiatric disorders represent 21st Century Medicine’s greatest global challenge.  They are 32 
the major cause, worldwide, of non-fatal burden of disease1. They account for around 30% 33 
of all years lived with disability, a contribution that is rising, especially in developing countries 34 
as the burden moves from communicable to non-communicable diseases1. With a life time 35 
prevalence greater than 10%, major depressive disorder accounts for a higher burden of 36 
disability than any other disorder, while schizophrenia, which contributes less to global 37 
burden due to its lower prevalence (around 1%), is the most severely disabling of all medical 38 
conditions2. It is stating the obvious that we need to develop and deliver more effective 39 
psychiatric prevention and treatment, but despite years of effort there have been few 40 
significant advances. There are a number of reasons for this, but prominent among them has 41 
been our lack of understanding of aetiology and pathogenesis, compounded by our reliance 42 
on observational and syndromic systems of diagnosis and classification.   43 
 44 
Concerns about psychiatric diagnosis and classification have been thrown into sharp relief 45 
by recent genomic studies that appear to show that risk alleles tend not to be specific to any 46 
particular disorder. In this perspective, we discuss the nature and extent of the evidence for 47 
shared risk alleles across psychiatric disorders and interpret that evidence within the context 48 
of how psychiatric diagnoses are made. We consider whether it is likely that risk variants for 49 
specific disorders exist, and how future studies might usefully illuminate alternative 50 
genotype-phenotype relationships.  We also consider some of the clinical implications 51 
emerging from pleiotropy. The focus of our discussion is the major psychiatric disorders such 52 
as schizophrenia, major mood disorders, autism spectrum disorders (ASD) and attention 53 
deficit hyperactivity disorder (ADHD), disorders for which research has faced conceptual and 54 
practical challenges that place them apart from dementias and from acute disturbances of 55 
mental function that are secondary to trauma, toxicity, or medical conditions.  56 
 57 
Psychiatric Diagnosis  58 
 59 
The Making of Psychiatric Diagnosis  60 
Psychiatric diagnoses are made on the basis of patient descriptions of their subjective 61 
experiences (e.g. energy, mood, perception, beliefs, appetite), and from observations of 62 
behaviour (e.g. bizarre activity, attention, self-care, social interaction) made by clinicians or 63 
reported by informants (e.g. family or carers, neighbours, teachers). Other factors are taken 64 
into consideration including functional impairment, developmental trajectory, and outcome. 65 
Ultimately a diagnosis is assigned to individuals who exhibit a minimum number of 66 
symptoms, behaviours, or outcomes, usually for a minimum period of time, with the proviso 67 
they do not meet criteria that exclude that diagnosis. The exclusion criteria are often 68 
subjective, requiring clinicians to judge that the clinical picture is not ‘better accounted for’ by 69 
another diagnosis, or that the picture is not ‘clearly caused by’ the effects of a psychoactive 70 
agent for example. In clinical practice, experience and intuition play a role, although semi-71 
standardized data acquisition tools and operationalized diagnostic criteria have been 72 
developed to minimize the impact of these subjective factors. These are used  primarily in 73 
research, but they are sometimes employed to aid diagnosis in the clinic (e.g. the Autism 74 
Diagnostic Observation Schedule).  75 
 76 
The Validity of Psychiatric Diagnosis  77 
As research data have accumulated it has become clear that the boundaries between 78 
diagnostic groups and between illness and wellness are not clear-cut, there is considerable 79 
heterogeneity within diagnostic categories, patients often have the clinical features of more 80 
than one disorder3, and the preponderance of those features in a particular individual can 81 
change markedly over time and development. Even with the most fastidious application of 82 
diagnostic criteria, there is no avoiding the fact that none of the clinical features are 83 
pathognomonic. For example, the occurrence of psychotic symptoms such as hallucinations 84 
and delusions, mood changes, and alterations in speech, activity level, behaviour and sleep, 85 
can indicate either a diagnosis of schizophrenia or bipolar disorder (BD). The frequent co-86 
occurrence of symptoms that could imply either major diagnostic label has led to a third 87 
category, schizoaffective disorder. Archetypal versions of each diagnosis exist, but for a 88 
large number of people, the distinction is based on relatively subjective judgments about the 89 
duration, quality, and severity of component signs and symptoms4. Outcome within 90 
diagnostic groups also varies widely, for example some people with a diagnosis of 91 
schizophrenia remain chronically symptomatic and impaired while others make a complete 92 
recovery5. Finally, as better-powered epidemiological studies have been carried out, it has 93 
become clear that the relatives of an individual with one psychiatric diagnosis are at 94 
increased risk for other diagnoses, undermining the genetic validity of current diagnostic 95 
approaches6.  96 
 97 
Biomarkers 98 
There have been extensive efforts to identify biomarkers indexing pathogenic mechanisms, 99 
including studies of blood markers (e.g. metabolites, cytokines, cortisol suppression), 100 
behavioural and cognitive measures, and various neuroimaging modalities7. However, this 101 
work has failed to deliver markers that can reliably distinguish between diagnoses, or to 102 
identify disease subgroups and, currently, there are no biomarkers in routine clinical use.  103 
For example, despite the extensive use of ever more sophisticated neuroimaging 104 
approaches, no measures have emerged that can separate people with a particular 105 
diagnosis from healthy individuals, much less distinguish between those with different 106 
diagnoses8. 107 
 108 
 109 
Molecular Genetic Findings in Psychiatry 110 
 111 
The robust identification of risk factors for psychiatric disease as indicated by DNA variation 112 
has been eagerly awaited for the insights this might provide into the basic biological 113 
architecture of, and relationships between, psychiatric phenotypes, as well as for its 114 
contributions to understanding disease mechanisms. In the last few years, genomic studies 115 
have begun to identify risk alleles in large numbers; although success has largely been 116 
confined to ASD, schizophrenia, and, to a lesser extent, BD and Major Depressive Disorder 117 
(MDD). Other psychiatric phenotypes have yet to be subjected to large-scale genome-wide 118 
studies.  119 
 120 
 121 
In ASD, the evidence implicating specific risk genes comes primarily from mutations that 122 
occur de novo in the form of large insertion-deletion mutations called copy number variants 123 
(CNVs) or rare coding variants (RCVs) that change the DNA sequence at a single, or a few, 124 
nucleotides. A recent synthesis of the ASD data (5,563 cases for de novo RCVs, 4687 cases 125 
for CNVs) reported high confidence associations to 65 genes and an additional 6 CNV loci9. 126 
All loci identified thus far confer large effects on risk, but with population frequencies less 127 
than one in a thousand, however this might simply reflect low power to detect smaller effect 128 
sizes. It should also be noted that there is emerging evidence that common genetic variation 129 
makes a substantial contribution to the variance in liability to ASD10 although, individual 130 
common alleles have not yet been robustly implicated.    131 
 132 
In schizophrenia, identified risk alleles span the full spectrum of frequencies. The largest 133 
analysis of genome-wide association (GWAS) data (up to 36,989 cases and 113,075 134 
controls) identified a total of 108 loci containing common alleles while that of rare CNVs 135 
(12,029-21,269 cases; 24,815- 81,821 controls) identified 11 strongly supported loci12. The 136 
latter was largely based on a meta-analysis of candidate CNVs, and a systematic genome 137 
wide CNV meta-analysis is awaited. Exome sequencing studies in schizophrenia have been 138 
smaller than those in ASD, and the evidence for RCVs is largely restricted to enrichments in 139 
pathways rather than specific genes13,14, although recently, a meta-analysis (4,264 140 
schizophrenia cases, 9,343 controls, 1,077 parent-proband trios) obtained genome-wide 141 
significant association between  schizophrenia and Loss-of-Function (LoF) RCVs in a gene 142 
which encodes the histone methytransferase SETD1A15. That study also reported a specific 143 
mutation in SETD1A that occurred in people with the disorder as a de novo mutation at a 144 
frequency far in excess of that expected by chance, providing confidence for pathogenicity of 145 
that specific mutation.  146 
 147 
In BD, GWAS and rare variant datasets are smaller than those of schizophrenia. The largest 148 
GWAS study (9,747 patients and 14,278 controls) identified 5 risk loci while, at the rare 149 
variant end of the spectrum, the only finding that meets a statistical threshold equivalent to 150 
genome wide significance is a duplication CNV at 16p.11.216. Finally, a recent GWAS17 151 
based upon MDD, as self-reported by customers of a consumer genetics company, identified 152 
15 loci for the disorder. It is particularly notable that only 15 loci were identified in a study 153 
including up to 130,620 cases and 347,620 controls. This underscores the fact that, while 154 
sample size may be critical for discovery genetics, it is not the only factor. Differences in 155 
other properties of disorders (e.g. disease prevalence, heterogeneity, phenotype definition, 156 
variance in risk contributed by individual alleles) can have a major impact.  157 
 158 
 159 
Pleiotropy  160 
 161 
The Nature of Pleiotropy  162 
The meaning of pleiotropy (Figure 1) depends on context18,19. We refer to genic pleiotropy 163 
when altered function of a gene influences multiple traits (note the term trait includes 164 
phenotypes that are not necessarily abnormal or disorders). Allelic pleiotropy, a subtype of 165 
genic pleiotropy, occurs when the same gene variant influences multiple traits. This is 166 
exemplified by phenylketonuria (PKU) in which causative mutations are pleiotropic for 167 
intellectual disability, lack of pigmentation, as well as various metabolic changes that can be 168 
measured in the blood. These two forms of biological pleiotropy, genic and allelic, suggest 169 
shared biology between disorders, but this is not the only explanation.  170 
 171 
Mediated pleiotropy occurs when an allele influences two traits, but its effects on one are 172 
secondary to more direct effects on the other. For example genetic variation at the fat mass 173 
and obesity associated (FTO) locus is pleiotropic for body mass index (BMI) and type 2 174 
diabetes (T2D), but the effects on T2D are secondary to those on BMI. In the case of PKU, 175 
the effects on intellectual function and pigmentation are mediated by the effects on the 176 
metabolic traits. As in these examples, mediated pleiotropy can be informative for 177 
understanding causal pathways to disease and, as we shall see, is often implicitly assumed 178 
in endophenotype studies, but the mediating relationship between the two traits can be 179 
complex and it does not necessarily imply that the two phenotypes share biological 180 
mechanisms.  181 
 182 
There are also numerous sources of false or pseudo pleiotropy. Pseudo pleiotropy can arise 183 
as a result of imprecision in gene mapping where two phenotypes are influenced by different 184 
genes in close proximity (Figure 1) but it can also arise from poor study design, associations 185 
that are due to chance (type II errors), and publication biases favouring reports of overlaps.  186 
 187 
Pleiotropy in Psychiatry and Developmental Disorders 188 
Evidence for cross disorder effects of genetic variation has come from studies showing that 189 
CNVs that influence risk for schizophrenia also often do so for ASD, intellectual disability (ID) 190 
developmental delay (Figure 2), and ADHD20. The majority of these apparently pleiotropic 191 
CNVs are multigenic, and therefore we cannot exclude pseudo pleiotropy in which distinct 192 
genes within the CNV cause each associated phenotype (Figure 1). However, the 193 
observation that every CNV known to increase risk of schizophrenia also does so for ID21 194 
makes co-localization alone an unlikely explanation. Moreover, the only ‘single gene’ CNV 195 
that is unequivocally associated with schizophrenia, deletion of the gene NRXN1 encoding 196 
the pre-synaptic protein neurexin 1 is also associated with ASD and with ID22. Sequencing 197 
studies have shown that as a group, genes impacted by LoF de novo mutations in 198 
schizophrenia are enriched for those affected by this same class of mutation in people with 199 
ASD and ID13. Moreover, several genes have been definitively implicated by de novo LoF 200 
mutations in each of developmental delay and ASD9,23 , while at an even finer level of 201 
resolution, the same LoF mutation in SETD1A that contributes high risk to schizophrenia 202 
also does so for severe ID and developmental delay15.  203 
 204 
The hypothesis of true pleiotropy in psychiatric and developmental disorders is also 205 
supported by common variants identified by GWAS. The International Schizophrenia 206 
Consortium (ISC) showed that hundreds, and perhaps thousands, of common alleles that 207 
increase risk for schizophrenia also do so for BD24 and it is now clear they also do so for 208 
MDD, and to a lesser extent, ASD, ADHD, Anorexia Nervosa, Obsessive Compulsive 209 
Disorder (Figure 3), as well as personality traits such as neuroticism25-27. A problem with 210 
inferring biological pleiotropy from GWAS is that the functional alleles (i.e. the alleles that 211 
changes function or expression of the gene and directly cause the association) responsible 212 
for the vast majority of the GWAS associations have not been identified. It is therefore 213 
possible that for any single cross-disorder association, different functional variants within the 214 
same or different genes might be responsible. However, the substantial genetic correlations 215 
between pairs of psychiatric phenotypes (Figure 3) are less readily explained by pseudo 216 
pleiotropy as this would require different functional alleles to be systematically and 217 
consistently tagged by the same GWAS allele across large numbers of loci.   218 
 219 
Taking the genomic data as a whole, true pleiotropy is by far the most parsimonious 220 
explanation for the majority of published cross disorder effects, and most of the findings 221 
support extensive allelic pleiotropy. A proviso here is that we must exclude mediated 222 
pleiotropy as an explanation. By definition, for one trait to be secondary to (or mediated by) 223 
another, the mediating trait must occur first. It follows that childhood onset disorders (e.g. 224 
ADHD) cannot be mediated by disorders with typically later ages of onset (e.g. 225 
schizophrenia, MDD).  However, it is theoretically possible that the converse is true, and that 226 
where alleles are pleiotropic for ID, schizophrenia, and ASD, ID is the primary phenotype 227 
influenced by those alleles, and that having ID causally increases risk of ASD and 228 
schizophrenia. There is certainly evidence that CNVs and de novo LoF mutations occur 229 
more frequently in people with psychiatric disorders who additionally have cognitive 230 
impairment9,13,28, an observation that has sometimes been interpreted as indicative of 231 
pleiotropy mediated through ID. However, this pattern of co-morbidity is not sufficient to 232 
establish mediated pleiotropy, indeed it is to be expected in cases where mutations have 233 
direct effects on two phenotypes. There are also powerful arguments against mediated 234 
pleiotropy as the sole explanation for this. First, in ASD, LoF de novo mutations tend to 235 
occur in the same sets of genes in probands with and without intellectual disability9. Second, 236 
at SETD1A, although LoF mutations are associated with both ID and schizophrenia, ID is not 237 
a prerequisite for schizophrenia in mutation carriers15. Third, ID is not universally seen in 238 
people with schizophrenia who carry de novo CNVs that are pleiotropic for both disorders28. 239 
Fourth, in the only study we are aware of that has explicitly undertaken a formal mediation 240 
analyses based on a rare variant, the 22q11 deletion CNV was found to have independent 241 
effects on cognitive and psychiatric traits (e.g. ADHD and ASD)30. The rare variant data are 242 
therefore inconsistent with the hypothesis that cross disorder findings are explained by 243 
mediated rather than allelic pleiotropy. The common variant findings are more complex, and 244 
will be considered further below.   245 
 246 
Pleiotropy in the context of complex disorders 247 
 248 
Pleiotropy is a challenging phenomenon in the context of highly polygenic disorders. 249 
Consider CNVs associated with at least two clinical outcomes, schizophrenia and intellectual 250 
disability, as well as being present in apparently unaffected carriers with no clinical 251 
phenotype. It has recently been shown31 that clinically unaffected CNV carriers perform 252 
worse on a range of measures of cognitive performance than do non-carrier controls, but 253 
better than people with either of the clinical diagnoses associated with the CNVs. Cognitive 254 
phenotyping therefore empirically demonstrates that CNVs impact on liability to quantitative 255 
traits that are overlooked when the only definition of ‘affected’ is that of a clinical diagnosis. 256 
What determines the final manifestations of increased liability in CNV carriers is not well 257 
understood, but an individual’s burden of common schizophrenia risk alleles is one important 258 
factor32. What might then be perceived as pleiotropic manifestations of a particular mutation 259 
(e.g. a CNV) may in fact more generally represent the net effects of an individual’s polygenic 260 
and environmental background on multiple traits representing various domains of brain 261 
function.  262 
 263 
Specific genes for psychiatric diagnoses  264 
 265 
Whether it is possible to link genotype to psychiatric phenotype is generally couched in 266 
terms of linear relationships between a gene and a single categorical diagnosis. In our 267 
opinion, the evidence summarized above suggests the outlook for relating genotype and 268 
phenotype in this way is not promising, although we recognize that there is a bias towards 269 
observing pleiotropy since studies are better powered to identify genetic similarities rather 270 
than differences.  271 
 272 
We do not suggest that risk alleles impact on psychiatric outcomes indiscriminately. For 273 
example duplication at 22q11 increases risk of ID and ASD, but is neutral for bipolar 274 
disorder, and protective for  schizophrenia33. Damaging rare mutations play a greater role in 275 
ID than in schizophrenia, in schizophrenia compared with mood disorder, and in psychiatric 276 
disorders with comorbid cognitive impairment16. With regard to common alleles, although 277 
many psychiatric disorders are genetically correlated, the degree of correlation between 278 
diagnostic classes is usually less than the degree of within disorder correlation26,34. These 279 
observations suggest that current diagnostic schemes do to some extent capture groups 280 
whose members have more in common with each other than they do with members of a 281 
general class ‘psychiatric disorder’. However, until we can directly measure liability, it is 282 
impossible to distinguish the phenotypic heterogeneity arising from true pleiotropic effects of 283 
a specific allele (even an allele of large effect) from that resulting from a person’s unique 284 
blend of risk factors. Directly measuring liability remains a distant goal; for now, identifying 285 
alternative approaches to patient stratification that index liability better than current 286 
diagnostic categories, and therefore might link more specifically to particular genotypes, is a 287 
more realistic aim. Some approaches to doing so are outlined in Box 1.   288 
 289 
 290 
Implications of Pleiotropy.  291 
 292 
The current system of psychiatric classification is not optimal, and alternative approaches 293 
are urgently required for clinical and fundamental research. The genetic findings do not, 294 
however, imply a similar urgency for fundamental changes in clinical practice as they do not 295 
provide the basis for a system with clear clinical value. Given the complexity of the 296 
relationships between disorders, and the likelihood that people with psychiatric illnesses 297 
differ quantitatively on multiple dimensions of function rather than categorically, seeking hard 298 
categorical boundaries that validly reflect aetiology seems a fool’s errand. Ultimately, we 299 
suspect the advances in genomic research will allow mapping between pathophysiological 300 
processes and domains of brain function (perhaps those outlined in RDoC, perhaps not) and 301 
between domains of brain function and the clinical picture and in doing so, will allow clinical 302 
measurements (for example types of cognitive test, brain imaging) that highlight 303 
perturbations that are pertinent to, and suggest interventions for, particular groups of 304 
patients. But what measures are likely to best achieve this, much less how to implement 305 
them in a clinical setting, is far from clear. Nevertheless, even now, the pervasive nature of 306 
shared risk factors, pleiotropy, and arbitrary diagnostic boundaries between disorders has 307 
clinical implications.  308 
 309 
As clinicians, we recognize the utility of diagnostic boundaries for therapeutic decision 310 
making, communication, and predicting (in a general way) certain outcomes and we do not 311 
suggest that clinicians abandon diagnosis using existing categories. However, rigid 312 
adherence to categories makes it easy to either overlook co-morbidity or, where it is 313 
detected, to inappropriately ascribe it to a diagnosis that has greater weight in the current 314 
diagnostic hierarchy. As a result, co-morbid syndromes may not be optimally treated. Given 315 
that pleiotropy implies that a person with one syndrome is at enhanced risk for a second 316 
syndrome, far from implying lax assessment, pleiotropy emphasizes the need for detailed 317 
on-going clinical monitoring, and assessments that go beyond the bare requirements of 318 
arriving at the best fitting diagnostic category. Moreover, by appreciating the increasing 319 
empirical basis for pleiotropy, clinicians can engage better in discussion with patients who 320 
are often bewildered by the range of diagnoses they may receive across their lifespans. 321 
Clinicians in other medical disciplines would not assign to a single clinical entity all the 322 
physical ailments associated with a pleotropic risk factor such as smoking, and there is no 323 
reason why psychiatrists should either.   324 
 325 
Children with congenital malformations, developmental delay, and ASD are already  being 326 
referred for molecular diagnostics, particularly for known pathogenic CNVs, but as the data 327 
continue to accumulate, more types of genetic findings will be incorporated.  It has been 328 
argued that CNV testing should be offered to people with other forms of psychiatric 329 
disorders; for now, the case is strongest for schizophrenia40 but we predict ADHD is likely to 330 
follow suit. The range of arguments for and against this are beyond the scope of this 331 
article41; here, we note that identifying carriers of high penetrance mutations is currently of 332 
limited value in psychiatry for precision medicine, but should testing be offered for 333 
counseling or predictive purposes, it is important to consider the pleiotropic effects of 334 
mutations. CNVs detected in children referred for testing may have important adult 335 
psychiatric implications, and conversely if adults are tested, pleiotropy has implications for 336 
their children and other relatives. The counseling challenges are substantial given the wide 337 
range of possible outcomes, and much of the data that are required to do this with precision, 338 
even for well-documented pathogenic CNVs, is lacking.  339 
 340 
The extensive pleiotropy reveled by psychiatric genetics also has important implications for 341 
interpreting mechanistic studies, whether in humans, using endophenotypes (Box 1), or in 342 
animal and cellular models. Even for high penetrance alleles, the possibility of pleiotropy 343 
implies the need for caution in ascribing a causal role in disease for particular brain imaging 344 
correlates of that mutation, or in a rodent or stem cell model, neurobiological outcomes. This 345 
issue has been discussed conceptually in the case of human endophenotypes and some of 346 
the statistical approaches to identifying mediation outlined42,43. The challenges to interpreting 347 
results from model systems are more testing and will require researchers to cast the net 348 
wider than is often the case in seeking the consequences of genetic risk factors and to relate 349 
their findings to comparable findings from clinical neuroscience. This will require the use of 350 
translatable measures and direct comparisons of the effects of genetic risk across levels of 351 
complexity3.   352 
 353 
Finally, on a positive note, pleiotropy may offer unsuspected therapeutic opportunities if it 354 
turns out that this is reflected in shared pathophysiology. It is not uncommon for psychiatrists 355 
to offer (off-label) treatments to patients with a particular diagnosis that are known to be 356 
effective in a different psychiatric disorder. In a very general sense, pleiotropy can be seen 357 
as offering some post-hoc justification for this, although we stress currently not at the level of 358 
any specific treatment. As new treatments are developed to target one disorder, it is likely 359 
that treatment will have a broader therapeutic role, and that wider patient populations may 360 
benefit from advances in research into a particular disorder.  361 
  362 
 363 
 364 
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Figure Legends 477 
Figure 1. Types of pleiotropy.  478 
 479 
Adjacent genes containing functional variants (FV; yellow circles) that together directly 480 
influence four distinct phenotypes (blue shapes). The three phenotypes directly influenced 481 
by FV1 and FV2 are examples of genic pleiotropy. The circle and pentagon phenotypes 482 
influenced by FV1 are examples of allelic pleiotropy in which the same variant rather than 483 
just the same gene influences multiple phenotypes. FV1 influences the triangle phenotype 484 
but this is indirect and only occurs through the direct effects of FV1 on the circle phenotype. 485 
This is mediated pleiotropy. Alleles at FV2 and FV3 are correlated (through linkage 486 
disequilibrium; LD) with the same single nucleotide polymorphism (SNP) Accordingly, that 487 
SNP will be associated with both phenotypes that are caused by those functional variants. 488 
The SNP is depicted midpoint between the genes but be positioned anywhere within the 489 
region of LD, including within one of the genes.  This is pseudo pleiotropy due to co-490 
localization.  This region is also prone to a deletion CNV which results in complete loss of 491 
function of both genes by virtue of which it is associated with all five phenotypes.  In a literal 492 
sense, all of the blue phenotypes in this instance are now examples of allelic pleiotropy 493 
(being directly caused by the same CNV allele at a single locus).  494 
 495 
 496 
Figure 2. Relative CNV Frequencies.  497 
 498 
Relative frequencies for schizophrenia associated CNVs. Frequency is expressed as fold 499 
increase in each disorder relative to the estimated population frequency. Data are taken 500 
from21 based on loci reported as schizophrenia associated12,21.  CNVs are described by 501 
cytogenetic position or the named syndrome most strongly affiliated with the locus. The 502 
approximate lifetime population risk for SZ is approximately 1% and for ID/ASD combined 503 
4%20. Abbreviations: SZ schizophrenia; ASD/ID autism spectrum disorder and ID intellectual 504 
disability combined. WBS Williams-Beuren Syndrome. PWS/AS. Prader-Willi 505 
Syndrome/Angelman Syndrome; VCFS Velo-cardio-facial syndrome; CNV copy number 506 
variant; del deletion; dup duplication.  507 
 508 
Figure 3. Genetic correlation between schizophrenia and selected psychiatric disorders. 509 
 510 
Psychiatric disorders showing significant evidence (P≤0.001) for overlaps between common 511 
variant contributions to schizophrenia and other psychiatric disorders. Overlaps are 512 
expressed as correlation in heritability (rg) captured by SNPs. Data are from44. Abbreviations: 513 
ADHD Attention Deficit Hyperactivity Disorder; OCD Obsessive Compulsive Disorder.  514 
 515 
Box 1: Patient Stratification  516 
There is general agreement that we need new approaches to patient stratification in 517 
research if we are to better understand gene-phenotype relationships, accelerate 518 
understanding of aetiology and pathogenesis, and inform mechanistic studies and treatment 519 
trials.  Generally speaking three ways in which we can move beyond the constraints of 520 
current diagnostic approaches have been proposed. Rather than being mutually exclusive, 521 
these can be thought of as targeting psychiatric disorders at different levels of conceptual, 522 
and aetiological complexity, from the molecular at one end to the function and behaviour of 523 
the whole human at the other. Models that attempt to capture this hierarchical complexity of 524 
have been proposed and discussed in detail elsewhere3.  525 
 526 
First, we can use clinical classifications that cut across or divide current diagnostic groups. 527 
These might be based upon the presence of absence of particular symptoms (e.g. 528 
hallucinations), syndromes (e.g. psychosis, depression) or other features such as course or 529 
outcome. This may aid the identification of risk factors and pathogenic mechanisms 530 
providing the strata map more closely onto these than do current diagnostic groupings. This 531 
approach also has the potential to help our understanding of the basis of heterogeneity. 532 
There is some evidence to support this type of approach, for example stratifying people with 533 
BD for the presence of psychotic symptoms predicts a higher burden of schizophrenia risk 534 
alleles, and, conversely, stratifying people with schizophrenia for presence of manic type 535 
symptoms predicts a higher burden of bipolar risk alleles35,36. These preliminary findings 536 
suggest that, across disorders, sets of syndromes have some shared biological basis, and 537 
support a model where disorders, as manifest in individuals, may be viewed as the 538 
confluence of partly orthogonal symptom dimensions.   539 
 540 
Second, stratification can be based on the presence of a particular aetiological factor (e.g. a 541 
rare high penetrance mutation, a particular environmental exposure) rather than clinical 542 
features. The assumption is that constraining the risk architecture will increase biological 543 
homogeneity, and allow researchers to focus on specific risk mechanisms and understand 544 
what factors lead to different outcomes, including resilience as well as risk. This type of 545 
approach also lends itself to complementary studies in cells and animals as well as humans. 546 
In psychiatry, this has yet to yield unqualified success, and, given evolutionary multi 547 
purposing of proteins, which may have different functions in different cells or cell 548 
compartments, even a single genetic variant might map onto different pathogenic 549 
mechanisms in carriers. While this is a theoretical concern, the fact that regardless of the 550 
specific psychiatric diagnoses (ID, ASD, schizophrenia), rare de novo and LoF mutations 551 
tend to impact upon similar broadly similar processes (e.g. glutamatergic pathways 552 
regulating synaptic plasticity, chromatin modifiers, and targets of fragile X mental retardation 553 
protein) suggests that individual mutations are likely to influence the same pathogenic 554 
mechanisms across disorders13 .  555 
 556 
Third, in attempting to relate risk factors and clinical phenotypes to underlying 557 
pathophysiology and mechanisms, stratification can be performed at the level of 558 
endophenotypes (intermediate phenotypes). One problem with this approach is the large 559 
number of potential endophenotypes including measures of cognition, brain structure, 560 
electrophysiology, and biochemistry. Moreover, initial claims that endophenotypes are likely 561 
to be less complex genetically than clinical disorders have not in general been supported37 562 
and perhaps this explains why failures to link endophenotypes to genetic risk38 are for now 563 
more notable than any reproducible successes. Nevertheless, this approach offers a means 564 
by which genetic risk can be linked to disturbances of brain function, and a framework for 565 
doing so has been implemented in the Research Domain Criteria (RDoC) project of the 566 
National Institutes of Mental Health39. The pleiotropic effects of many risk alleles are clear 567 
reminders that there are pitfalls associated with using this approach to chart the pathways 568 
mediating the effects of genetic risk on clinical phenotypes (see main text).   569 
 570 
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